[Elsevier] TET2 mutation as prototypic clonal hematopoiesis lesion |
Reward10points
|
10
Updated Findings and Biomarker Analysis From the Ongoing Phase 1 Study of Enhancer of Zeste Homolog 2 (EZH2) Inhibitor CPI-0209 in Patients With Advanced Solid Tumors
10
Preliminary Clinical Data From Ongoing Phase 2 Study With Enhancer of Zeste Homolog 2 (EZH2) Inhibitor CPI-0209 in Patients With Advanced Solid Tumors or Hematologic Malignancies
10
The extracellular matrix integrates mitochondrial homeostasis
10
Bimetallic and multimetallic MOFs and their derivatives
10
DNMT1: A key drug target in triple-negative breast cancer
